Phase 1 Trial Testing Chondrial’s Potential FA Therapy, CTI-1601, Starts Dosing Patients

A Phase 1 trial evaluating Chondrial Therapeutic’s investigational therapy CTI-1601 as a treatment for Friedreich’s ataxia patients has started dosing patients. The therapy was recently granted rare pediatric disease and fast track designations by the U.S. Food and Drug Administration (FDA), in addition to its…